FIGURE 2: Three different engineered cell therapy strategies based on proteomic analysis. A. A “Locking-on” CAR-T concept harnesses the high abundance and hematopoietic specificity of CD48 or CD38 binding to increase avidity of anti-BCMA CAR-T. B. Acute treatment with lenalidomide increases MUC-1 expression on myeloma cells, improving anti-MUC-1 CAR-T activity. C. Proof-of-concept of stand-alone CAR-T against CCR10 using its natural ligand CCL27 as an antigen recognition domain. Figure created with BioRender

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.